Deregulation Aims to Lower Costs and Increase Access to Veterinary Vaccines

In a important move to bolster it’s economic deregulation policy, the Argentinian government is dismantling barriers in the veterinary vaccine market. This initiative follows the previously announced elimination of import tariffs on mobile phones and now targets the production and distribution of veterinary vaccines, notably those combating Afitase fever (Foot-and-Mouth Disease).

Senasa Streamlines Import Process for Veterinary Products

The National agrifood Health and Quality Service (Senasa) has officially published resolution 333/2025,introducing a revamped system for authorizing the import of veterinary products already registered in other countries. This new framework emphasizes the recognition of certifications from equivalent foreign regulatory bodies, effectively removing local technical requirements deemed overly restrictive. Moreover, the resolution mandates a significantly reduced processing time of just 90 administrative business days for import permits, a stark contrast to the previous delays that could extend up to two years.

Afitase Fever Vaccine Market Faces Increased Competition

This policy shift directly impacts the market for Afitase fever vaccines, which are mandatory for livestock across Argentina. For decades, this market has been largely dominated by Bagó biogenesis, the sole laboratory authorized to supply doses meeting the stringent requirements of the national regulator. Though,the National Competition Commission (CNDC) has voiced concerns,issuing a technical opinion highlighting regulatory barriers that could be unjustified by the competition in the provision of these essential vaccines.

CNDC Recommendations prompt Regulatory Overhaul

Senasa’s decision to overhaul the import process aligns with recommendations from the CNDC, which intervened following complaints from Tecnovax laboratory and the Rural Society of Southern Salta. These parties argued that the existing system unduly restricted competition through specific regulations. A key point of contention was the requirement for the Podal Generalization Protection (PGP) test for registering and importing new vaccines. This methodology,considered both costly and time-consuming,is no longer standard practice in other countries within the region.

Addressing Anti-Competitive Practices

The CNDC also criticized the refusal to acknowledge international certifications, even from countries with robust and effective animal health programs, characterizing it as a barrier to competition. Additional restrictions were identified concerning the operations of health entities involved in vaccine distribution and management.According to the CNDC’s findings, these limitations reduced options for livestock producers and inflated operational costs.

Price Discrepancies Highlighted by Government Official

Federico Sturzenegger, Minister of Deregulation and Transformation of the state, took to social media to illustrate the price disparities. He pointed out that Argentina had only one approved vaccine against Aphid fever, while Paraguay offered seven. He further noted that the local vaccine cost $1.20 per dose, significantly higher than the prices in Paraguay ($0.35) and Uruguay ($0.72).sturzenegger also emphasized that the same Argentinian laboratory supplying the local market was selling vaccines in Paraguay at substantially lower prices.

In Argentina there was a single vaccine enabled against the Aphid fever, while in Paraguay there were seven. The local vaccine cost $ 1.20 per dose, while in Paraguay it was sold to $ 0.35 and in Uruguay at 0.72 dollars. In addition, the same Argentine laboratory that supplied the local market also provided vaccines in Paraguay, at significantly lower prices.

Federico Sturzenegger, Minister of Deregulation and Transformation of the State

Implications for Livestock Producers and the Veterinary Industry

This deregulation initiative is expected to have a profound impact on Argentinian livestock producers, possibly lowering costs and increasing access to a wider range of veterinary vaccines. The move also signals a significant shift in the veterinary industry, fostering greater competition and potentially driving innovation in vaccine growth and distribution.The long-term effects will be closely watched by stakeholders across the agricultural sector.

Revamping Regulations for a Competitive Livestock Sector

Argentina is overhauling its regulations concerning veterinary products,a move projected to save the livestock industry approximately $100 million annually. This initiative, spearheaded by president Javier Milei, seeks to eliminate technical barriers and expedite the approval process for products already authorized in countries with comparable regulatory standards. The focus is on fostering competition and reducing costs for livestock producers.

Addressing the Afitosa Vaccine Bottleneck

The impetus for these regulatory changes stemmed from concerns surrounding the Afitosa fever vaccine. Previously,the technical specifications for the tetravalent vaccine in Argentina acted as a barrier to entry for international competitors. the vaccine’s formulation included four strains, two of which were no longer circulating, effectively granting a monopoly to a national laboratory possessing the necessary strains to meet the outdated norm.

Economy Minister Luis Caputo emphasized the importance of this shift, stating that it promotes access to quality supplies with international standards. He highlighted the price disparity in Afitosa vaccine costs: while the local vaccine cost $1.36 per dose in December 2023 and currently stands around $1.20, similar vaccines are available for $0.37 in Paraguay and $0.50 in Uruguay. This price difference underscores the potential for significant cost savings through increased competition.

Dismantling Barriers to Entry: A Multi-Pronged Approach

The regulatory overhaul extends beyond vaccine formulations. The National Commission for the Defense of Competition (CNDC) has recommended further reforms to the dose submission scheme. These recommendations include:

• Eliminating the requirement of non-profit legal status for health entities involved in vaccine administration.
• Opening the market to individual veterinarians with current registration.
• Removing exclusive geographical allocations for foundations or entities, allowing producers to freely choose their veterinary service providers.

These changes aim to empower producers and foster a more competitive market for veterinary services.

Promoting Price Competition in Veterinary Services

Further recommendations from the CNDC include repealing Article 16 of Sagpya Resolution 108/2001. This article currently sets tariffs for sanitary entities based on reference values steadfast by Senasa (National Agri-Food Health and Quality Service). By removing this price control mechanism, the goal is to allow prices to be determined freely between parties, further promoting competition and potentially leading to lower costs for producers.

broadening the Scope: A New Standard for Veterinary Products

While the Afitosa vaccine issue served as the catalyst, the new Senasa standard, Resolution 333/2025, has a broader scope. It applies to a wide range of veterinary products, including medicines, diagnostic kits, and biological products for animals. The key requirements for imported products include a free sale certificate,the dossier approved by the health authority of the country of origin,and compliance with good manufacturing practices. This complete approach aims to ensure the quality and safety of veterinary products while streamlining the approval process.

Looking Ahead: Impact on argentina’s Livestock Industry

The implementation of these regulatory changes is expected to have a significant impact on Argentina’s livestock industry. By reducing costs, fostering competition, and streamlining the approval process for veterinary products, the government aims to enhance the competitiveness of the sector and support the livelihoods of livestock producers. The success of these reforms will depend on effective implementation and ongoing monitoring to ensure that the intended benefits are realized.

Streamlining Vaccine Access: A New Era for Public Health?

Argentina is on the cusp of a significant shift in its vaccine market, driven by recent regulatory adjustments designed to broaden access and foster competition. These changes, while not immediately impacting current vaccination campaigns, are projected to pave the way for the importation of new vaccines starting in 2026. The move aims to address previous limitations that restricted the entry of products already vetted in comparable international markets.

The core objective is multifaceted: to drive down the cost per dose, diversify the available vaccine options, and empower producers to select suppliers that best align with the health policies mandated by Senasa, the national food safety and quality service. This strategic overhaul could have profound implications for public health initiatives and the overall affordability of preventative care.

The Mechanics of Change: Certification and Computerization

A key component of the new regulatory landscape is Article 6, which stipulates that upon successful completion of the required procedures, a certificate of use and marketing will be granted, enabling the sale of the product within Argentina. This certification process is coupled with mandatory audits and controls, ensuring adherence to quality standards and safety protocols.

Furthermore, the regulatory processes are being progressively digitized through the Sig-Trámites system, a move towards greater efficiency and transparency. This computerization initiative is expected to streamline applications and approvals, reducing bureaucratic hurdles and accelerating the time-to-market for new vaccines.

Potential Beneficiaries and Market Dynamics

Among the companies poised to capitalize on this regulatory shift is Tecnovax, which is actively pursuing a strategy to incorporate imported doses from Brazil. This highlights the potential for increased cross-border collaboration and the introduction of innovative vaccine solutions to the Argentine market.

The anticipated increase in competition could lead to more favorable pricing for consumers and healthcare providers.According to a 2024 report by the World Health Organization, increased competition in pharmaceutical markets has been shown to reduce prices by as much as 30%, making essential medicines more accessible to vulnerable populations. This regulatory change in Argentina could mirror these positive trends, improving public health outcomes and reducing healthcare disparities.

CNDC’s Perspective: Dismantling Barriers to Entry

The National Commission for the Defense of Competition (CNDC) played a crucial role in advocating for these regulatory changes. The CNDC argued that the previous framework unduly restricted the entry of products already proven safe and effective in similar markets. The modification of these rules seeks to reduce the price per dose,expand the available offer and allow each producer to access the supplier that it deems most convenient for the execution of the health policies established by the Senasa.

By dismantling these barriers to entry, the CNDC aims to foster a more dynamic and competitive vaccine market, ultimately benefiting both producers and consumers. This aligns with broader efforts to promote economic efficiency and ensure equitable access to essential healthcare resources.